Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: A randomized phase II pilot study

Daniel A. Lim, Phiroz Tarapore, Edward Chang, Marlene Burt, Lenna Chakalian, Nicholas Barbaro, Susan Chang, Kathleen R. Lamborn, Michael W. McDermott

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Seizures are common in patients with gliomas, and phenytoin (PHT) is frequently used to control tumor-related seizures. PHT, however, has many undesirable side effects (SEs) and drug interactions with glioma chemotherapy. Levetiracetam (LEV) is a newer antiepileptic drug (AED) with fewer SEs and essentially no drug interactions. We performed a pilot study testing the safety and feasibility of switching patients from PHT to LEV monotherapy for postoperative control of glioma-related seizures. Over a 13-month period, 29 patients were randomized in a 2:1 ratio to initiate LEV therapy within 24 h of surgery or to continue PHT therapy. 6 month follow-up data were available for 15 patients taking LEV and for 8 patients taking PHT. In the LEV group, 13 patients (87%) were seizure-free. In the PHT group, 6 patients (75%) were seizure-free. Reported SEs at 6 months was as follows (%LEV/%PHT group): dizziness (0/ 14), difficulty with coordination (0/29), depression (7/14) lack of energy or strength (20/43), insomnia (40/43), mood instability (7/0). The pilot data presented here suggest that it is safe to switch patients from PHT to LEV monotherapy following craniotomy for supratentorial glioma. A large-scale, double-blinded, randomized control trial of LEV versus PHT is required to determine seizure control equivalence and better assess differences in SEs.

Original languageEnglish (US)
Pages (from-to)349-354
Number of pages6
JournalJournal of Neuro-Oncology
Volume93
Issue number3
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

etiracetam
Craniotomy
Phenytoin
Glioma
Seizures
Safety
Drug Interactions

Keywords

  • Anticonvulsant
  • Craniotomy
  • Glioma
  • Levitiracetam
  • Phenytoin
  • Seizure

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology

Cite this

Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy : A randomized phase II pilot study. / Lim, Daniel A.; Tarapore, Phiroz; Chang, Edward; Burt, Marlene; Chakalian, Lenna; Barbaro, Nicholas; Chang, Susan; Lamborn, Kathleen R.; McDermott, Michael W.

In: Journal of Neuro-Oncology, Vol. 93, No. 3, 2009, p. 349-354.

Research output: Contribution to journalArticle

Lim, Daniel A. ; Tarapore, Phiroz ; Chang, Edward ; Burt, Marlene ; Chakalian, Lenna ; Barbaro, Nicholas ; Chang, Susan ; Lamborn, Kathleen R. ; McDermott, Michael W. / Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy : A randomized phase II pilot study. In: Journal of Neuro-Oncology. 2009 ; Vol. 93, No. 3. pp. 349-354.
@article{22791003d13b44c689587386a24eb3b9,
title = "Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: A randomized phase II pilot study",
abstract = "Seizures are common in patients with gliomas, and phenytoin (PHT) is frequently used to control tumor-related seizures. PHT, however, has many undesirable side effects (SEs) and drug interactions with glioma chemotherapy. Levetiracetam (LEV) is a newer antiepileptic drug (AED) with fewer SEs and essentially no drug interactions. We performed a pilot study testing the safety and feasibility of switching patients from PHT to LEV monotherapy for postoperative control of glioma-related seizures. Over a 13-month period, 29 patients were randomized in a 2:1 ratio to initiate LEV therapy within 24 h of surgery or to continue PHT therapy. 6 month follow-up data were available for 15 patients taking LEV and for 8 patients taking PHT. In the LEV group, 13 patients (87{\%}) were seizure-free. In the PHT group, 6 patients (75{\%}) were seizure-free. Reported SEs at 6 months was as follows ({\%}LEV/{\%}PHT group): dizziness (0/ 14), difficulty with coordination (0/29), depression (7/14) lack of energy or strength (20/43), insomnia (40/43), mood instability (7/0). The pilot data presented here suggest that it is safe to switch patients from PHT to LEV monotherapy following craniotomy for supratentorial glioma. A large-scale, double-blinded, randomized control trial of LEV versus PHT is required to determine seizure control equivalence and better assess differences in SEs.",
keywords = "Anticonvulsant, Craniotomy, Glioma, Levitiracetam, Phenytoin, Seizure",
author = "Lim, {Daniel A.} and Phiroz Tarapore and Edward Chang and Marlene Burt and Lenna Chakalian and Nicholas Barbaro and Susan Chang and Lamborn, {Kathleen R.} and McDermott, {Michael W.}",
year = "2009",
doi = "10.1007/s11060-008-9781-4",
language = "English (US)",
volume = "93",
pages = "349--354",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy

T2 - A randomized phase II pilot study

AU - Lim, Daniel A.

AU - Tarapore, Phiroz

AU - Chang, Edward

AU - Burt, Marlene

AU - Chakalian, Lenna

AU - Barbaro, Nicholas

AU - Chang, Susan

AU - Lamborn, Kathleen R.

AU - McDermott, Michael W.

PY - 2009

Y1 - 2009

N2 - Seizures are common in patients with gliomas, and phenytoin (PHT) is frequently used to control tumor-related seizures. PHT, however, has many undesirable side effects (SEs) and drug interactions with glioma chemotherapy. Levetiracetam (LEV) is a newer antiepileptic drug (AED) with fewer SEs and essentially no drug interactions. We performed a pilot study testing the safety and feasibility of switching patients from PHT to LEV monotherapy for postoperative control of glioma-related seizures. Over a 13-month period, 29 patients were randomized in a 2:1 ratio to initiate LEV therapy within 24 h of surgery or to continue PHT therapy. 6 month follow-up data were available for 15 patients taking LEV and for 8 patients taking PHT. In the LEV group, 13 patients (87%) were seizure-free. In the PHT group, 6 patients (75%) were seizure-free. Reported SEs at 6 months was as follows (%LEV/%PHT group): dizziness (0/ 14), difficulty with coordination (0/29), depression (7/14) lack of energy or strength (20/43), insomnia (40/43), mood instability (7/0). The pilot data presented here suggest that it is safe to switch patients from PHT to LEV monotherapy following craniotomy for supratentorial glioma. A large-scale, double-blinded, randomized control trial of LEV versus PHT is required to determine seizure control equivalence and better assess differences in SEs.

AB - Seizures are common in patients with gliomas, and phenytoin (PHT) is frequently used to control tumor-related seizures. PHT, however, has many undesirable side effects (SEs) and drug interactions with glioma chemotherapy. Levetiracetam (LEV) is a newer antiepileptic drug (AED) with fewer SEs and essentially no drug interactions. We performed a pilot study testing the safety and feasibility of switching patients from PHT to LEV monotherapy for postoperative control of glioma-related seizures. Over a 13-month period, 29 patients were randomized in a 2:1 ratio to initiate LEV therapy within 24 h of surgery or to continue PHT therapy. 6 month follow-up data were available for 15 patients taking LEV and for 8 patients taking PHT. In the LEV group, 13 patients (87%) were seizure-free. In the PHT group, 6 patients (75%) were seizure-free. Reported SEs at 6 months was as follows (%LEV/%PHT group): dizziness (0/ 14), difficulty with coordination (0/29), depression (7/14) lack of energy or strength (20/43), insomnia (40/43), mood instability (7/0). The pilot data presented here suggest that it is safe to switch patients from PHT to LEV monotherapy following craniotomy for supratentorial glioma. A large-scale, double-blinded, randomized control trial of LEV versus PHT is required to determine seizure control equivalence and better assess differences in SEs.

KW - Anticonvulsant

KW - Craniotomy

KW - Glioma

KW - Levitiracetam

KW - Phenytoin

KW - Seizure

UR - http://www.scopus.com/inward/record.url?scp=67349218398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349218398&partnerID=8YFLogxK

U2 - 10.1007/s11060-008-9781-4

DO - 10.1007/s11060-008-9781-4

M3 - Article

C2 - 19169651

AN - SCOPUS:67349218398

VL - 93

SP - 349

EP - 354

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -